Hoda Syed A, Hoda Rana S, Merlin Scott, Shamonki Jamie, Rivera Michael
Department of Pathology, Weill Medical College of Cornell University, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, USA.
Adv Anat Pathol. 2006 Nov;13(6):308-15. doi: 10.1097/01.pap.0000213048.69564.26.
Lymphovascular invasion (LVI) by tumor cells is histologically evident in approximately 15% of invasive mammary duct carcinomas and is present in approximately 10% of cases with pathologically negative lymph nodes. LVI is indicative of unfavorable prognosis in the breast cancer-as manifested by increased local failure and reduced overall survival. It is for this reason that LVI is routinely included in the evaluation and reporting of all breast cancers. There are a variety of interpretative difficulties in the histopathologic assessment of LVI, and the clinical implications of any misinterpretation can be profound. This brief review seeks to highlight the difficulties in the evaluation of LVI in breast cancer.
肿瘤细胞的淋巴管浸润(LVI)在大约15%的浸润性乳腺导管癌中组织学表现明显,且在大约10%病理检查淋巴结阴性的病例中存在。LVI提示乳腺癌预后不良,表现为局部复发增加和总生存率降低。正因如此,LVI常规纳入所有乳腺癌的评估和报告中。在LVI的组织病理学评估中存在多种解释上的困难,任何错误解释的临床影响可能是深远的。本简要综述旨在突出乳腺癌LVI评估中的困难。